Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis. J of Skin 2023, 7 (2), s154. https://doi.org/10.25251/skin.7.supp.154.